🚨Final 48 Hours: Early-Bird Registration closes on Friday, November 20, at 11:59 PM KST (UTC+9) — just 2 days away. Register now and save!
🔗Register Here ▶️ complex-pci.com/2026/attend_…#LMSummit2026
Can we stop aspirin after just one month of DAPT following PCI without compromising ischaemic safety?
An analysis of 11 randomized trials involving 37,443 patients found that P2Y12-inhibitor monotherapy substantially reduced bleeding, with broadly comparable ischaemic outcomes following one- versus three-month aspirin withdrawal. However, an early ischaemic signal with near-immediate withdrawal highlights the importance of timing.
Does the future of post-PCI antiplatelet therapy lie in earlier aspirin withdrawal?
Read the study and share your perspective!
#Cardiology#CardioTwitter#PCI#AntiplateletTherapy#InterventionalCardiologypubmed.ncbi.nlm.nih.gov/4283…@drhbulluck
Yamaguchi et al. extend cardiac CT beyond coronary anatomy. Low-dose cine CT during the recirculation phase provided reproducible ventricular and atrial functional measurements compared with CMR.
doi.org/10.1016/j.jcct.2026.…
🌍 ISICAM 2026: A World-Class Interventional Cardiology Event!
A remarkable achievement and a new milestone for interventional cardiology in Indonesia!
🏆 2,111 Participants
📑 256 Abstract Submissions
🌏 67 International Faculty
🎓 39 Symposia
🤝 5 Joint Sessions
🔬 8 Workshops for Interventional Cardiologists
🩺 4 Workshops for Nurses & Allied Health Professionals
❤️ 18 Live Cases from 4 overseas centers across 4 countries
The 18th ISICAM 2026 brought together leading experts, international faculty, researchers, and healthcare professionals under the theme:
“Translating Evidence into Practice in Cardiovascular Intervention.”
Three days of scientific excellence, knowledge sharing, hands-on learning, international collaboration, and inspiring discussions.
Thank you to all faculty members, participants, abstract presenters, partners, and the organizing committee for making ISICAM 2026 an outstanding success!
ISICAM — Raising the Standard of Interventional Cardiology in Indonesia and Beyond! 🚀
#ISICAM2026#WorldClassCardiology#InterventionalCardiology#CardiovascularInnovation#ScientificExcellence
BUYING A PHOTON-COUNTING CT SCANNER DOES NOT AUTOMATICALLY CREATE A PHOTON-COUNTING CT PRACTICE.
It gives you the technology.
NOT NECESSARILY THE EXPERTISE TO USE IT.
A new review published in Cancer Imaging explores the clinical applications of Photon-Counting CT in abdominal oncology.
Beyond the expected improvements in spatial resolution, contrast-to-noise ratio, and spectral imaging, the authors highlight something much more important.
PCCT REQUIRES A DIFFERENT APPROACH TO CLINICAL IMAGING.
Consider a few examples:
➤ 40 keV may improve pancreatic tumor conspicuity, but it is not necessarily optimal for detecting liver lesions.
➤ In renal imaging, low-keV reconstructions may increase pseudoenhancement and lead to incorrect lesion characterization.
➤ Ultra-high spatial resolution is not always the best choice for quantitative imaging.
➤ Better image quality does not automatically translate into better diagnostic accuracy or clinical outcomes.
MY TAKE
Photon-Counting CT is not simply conventional CT with a better detector.
It is a different imaging technology, with capabilities that require specific knowledge, protocols, reconstruction strategies, and interpretation skills.
And this has important consequences.
YOU CANNOT JUST COPY YOUR OLD CT PROTOCOLS, PRESS START, AND EXPECT A REVOLUTION.
You need dedicated training.
You need experienced radiologists and technologists.
You need protocol optimization, quality control, and continuous clinical evaluation.
And above all, you need to understand WHY, WHEN, AND HOW to exploit the technology for each patient.
The scanner is only the starting point.
THE REAL UPGRADE IS NOT JUST THE HARDWARE.
IT IS THE KNOWLEDGE BEHIND IT.
Jadav V et al. Clinical applications of photon-counting CT in abdominal oncologic imaging: a primer for developing a clinical practice. Cancer Imaging. 2026;26:159. DOI: 10.1186/s40644-026-01107-8.
#PhotonCountingCT#PCCT#Radiology#MedicalImaging#OncologicImaging#RadiologyEducation#ClinicalInnovation
PS: the exact same is true for Cardiovascular Imaging. If you think you get a PCCT and then you exploit the advantages by approaching it as the previous EiD CT scanner you are on the wrong track and you will lose time, money and opportunity. Research, education, and a complete change of approach are mandatory.
The SirPAD trial data established sirolimus-coated balloon angioplasty as an effective alternative to uncoated-balloon angioplasty for infrainguinal #cvPAD, with meaningful reductions in both amputation and CLI-driven #Revascularization.
🔗 Learn more: bit.ly/4AfuV0v
#JACCCEP study: In persistent #AFib, baseline LA volume index did not predict arrhythmia recurrence after first-time ablation but was associated with higher AFib burden and persistent recurrence phenotype at 1-year postablation.
bit.ly/4iTpFb2#epAblation
1/8 🧵
Can PCI be declared non-inferior to CABG while offering no benefit—or potentially worse outcomes—than optimal medical therapy?
YES.
This is one of the most overlooked methodological problems in coronary revascularization trials.
Here’s why. 👇
Revascularization timing in ACS and Complex Non-cultprit Lesions: Insights From the BIOVASC Trial. Lesion complexity alone should not mandate a staged strategy @espogiov@drnvanmieghemahajrnls.org/4fqdbGT
In nearly 72,000 patients over 17 years, Rozanski et al. document the rise of CCTA, decline of SPECT-MPI and evolving role of physiologic imaging—trends that anticipated and align with today's guidelines.
doi.org/10.1016/j.jcct.2026.…
In a RCT, no difference in radial spasm was detected between puncture sites located closer to/farther from radial styloid process. Near-styloid access was associated with better puncture efficiency and fewer radial occlusions and hematomas onlinelibrary.wiley.com/doi/…@ccijournal
TCTAP is heading to 🇮🇩Jakarta for #ISICAM2026!
Be sure to stop by our booth, and don't miss the joint session on Left Main PCI, where experts from Korea and Indonesia will share their perspectives on key challenges in complex coronary interventions.
See you soon! 👋#TCTAP2027
Stopping GLP-1 treatment linked to twice the risk of heart attack, stroke or death compared with continuing, in people with type 2 diabetes and no cardiovascular disease, according to a new study.
Find out more in @LancetRH_Europe: spkl.io/60137wUtS